As of May 28
| +0.18 / +0.40%|
The 25 analysts offering 12-month price forecasts for GlaxoSmithKline have a median target of 47.00, with a high estimate of 55.25 and a low estimate of 40.93. The median estimate represents a +4.93% increase from the last price of 44.79.
The current consensus among 30 polled investment analysts is to Hold stock in GlaxoSmithKline. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.